Smilja Djurdjevic

Dr. Smilja Djurdjevic

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2018 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
PLPeter N. Lee
Peter N. Lee
SDSmilja Djurdjevic
Smilja Djurdjevic
RWRolf Weitkunat
Rolf Weitkunat
GBGizelle Baker
Gizelle Baker
We estimated, using previously described methodology, the population health impact of introducing a reduced-risk tobacco product (RRP) into Japan. Various simulations were carried out to understand the impact on the population in different situations over a 20-year period from 1990. The overall reduction in tobacco-attributable deaths from lung cancer (LC), ischemic heart disease (IHD), stroke, and chronic obstructive pulmonary disease (COPD) for men and women combined was estimated to be 269,916 over the period if tobacco use disappeared completely at baseline. In contrast, reductions ranging from 232,519 to 167,041 deaths were estimated if the RRP totally replaced smoking at baseline (assuming that switching to it had an effect equivalent to 70%–90% of the effect of quitting). If, more plausibly, the RRP were introduced at baseline, with uptake rates consistent with the known uptake of the RRP IQOS®, the reductions would still be substantial (from 86,885 to 65,126 deaths). Expressed as a percentage of attributable deaths, these proportions are larger than those for the U.S., based on likely uptake rates. We discuss various limitations of the approach, though none should affect the conclusion that the introduction of an RRP into Japan will substantially reduce tobacco-related deaths.

16 May 2018 in Healthcare
Verified
Journal Article
Open access
PDF file
SDSmilja Djurdjevic
Smilja Djurdjevic
PLPeter Lee
Peter Lee
RWRolf Weitkunat
Rolf Weitkunat
ZSZheng Sponsiello-Wang
Zheng Sponsiello-Wang
FLFrank Lüdicke
Frank Lüdicke
GBGizelle Baker
Gizelle Baker
Philip Morris International (PMI) has developed the Population Health Impact Model (PHIM) to quantify, in the absence of epidemiological data, the effects of marketing a candidate modified risk tobacco product (cMRTP) on the public health of a whole population. Various simulations were performed to understand the harm reduction impact on the U.S. population over a 20-year period under various scenarios. The overall reduction in smoking attributable deaths (SAD) over the 20-year period was estimated as 934,947 if smoking completely went away and between 516,944 and 780,433 if cMRTP use completely replaces smoking. The reduction in SADs was estimated as 172,458 for the World Health Organization (WHO) 2025 Target and between 70,274 and 90,155 for the gradual cMRTP uptake. Combining the scenarios (WHO 2025 Target and cMRTP uptake), the reductions were between 256,453 and 268,796, depending on the cMRTP relative exposure. These results show how a cMRTP can reduce overall population harm additionally to existing tobacco control efforts.

10 April 2018 in Preprints.org
Verified
Preprint
Open access
SDSmilja Djurdjevic
Smilja Djurdjevic
PLPeter N. Lee
Peter N. Lee
RWRolf Weitkunat
Rolf Weitkunat
ZSZheng Sponsiello-Wang
Zheng Sponsiello-Wang
FLFrank Lüdicke
Frank Lüdicke
GBGizelle Baker
Gizelle Baker
Philip Morris International (PMI) has developed the Population Health Impact Model (PHIM) to quantify, in the absence of epidemiological data, the effects of marketing a candidate modified risk tobacco product (cMRTP) on the public health of a whole population. Various simulations were performed to understand the harm reduction impact on the U.S. population over a 20-year period under various scenarios. The overall reduction in smoking attributable deaths (SAD) over the 20-year period was estimated as 934,947 if smoking completely went away and between 516,944 and 780,433 if cMRTP use completely replaces smoking. The reduction in SADs was estimated as 172,458 for the World Health Organization (WHO) 2025 Target and between 70,274 and 90,155 for the gradual cMRTP uptake. Combining the scenarios (WHO 2025 Target and cMRTP uptake), the reductions were between 256,453 and 268,796, depending on the cMRTP effective dose. These results show how a cMRTP can reduce overall population harm additionally to existing tobacco control efforts.

1 November 2019 in European Journal of Public Health
Verified
Journal Article
Closed access
PDF file
SDSmilja Djurdjevic
Smilja Djurdjevic
GBG Baker
G Baker
Philip Morris International has developed a Population Health Impact Model (PHIM) to estimate the effects of marketing Reduced-Risk Products on population health. The PHIM creates a disease-specific risk profile for each individual based on their age and smoking history. To create a risk profile, the PHIM calculates, at each year of age, the excess relative risk (ERR=relative risk [RR]-1) by multiplying an individual’s equivalent dose (ED) by the ERR for smoking vs. never smoking. ED is defined as 0 at birth and stays at 0 while the individual is a non-smoker. Once tobacco use starts, the individual’s ED rises toward the relative exposure (RE) corresponding to the product used. Following quitting or change of product, ED moves toward the new value of RE. The model uses estimates of age- and disease-specific current smoking RRs and ERR half-lives following cessation, derived from meta-analyses of published data. Estimates of the half-life of excess risk are also used when estimating rise in ERR following initiation or change in ERR following a change in product use. We apply the method to data for the four main smoking-related diseases; lung cancer, ischemic heart disease, stroke, and chronic obstructive pulmonary disease. For a given disease and age group, the PHIM can derive estimates of the average ERR for each individual in the population studied. Given an overall estimate of absolute population risk, the PHIM can then also be used to derive estimates of absolute risk for each individual. Key messages: Health impact modeling can be used to understand the individual and population impacts of introducing reduced risk tobacco products. Footnote: *Reduced-Risk Products are products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products vs continued smoking.